One good thing is "The Licensing Agreement continues in full force and effect pending the
Arbitrator's decision". Even if POH doesn't get a big amount but retain the ownership of TPM®/Daptomycin injectable, Mylan will need to pay POH % royalties. Few % to POH vs delays/ not launching the product into huge daptomycin market is on POH side. Few % for POH will be big money, plus recognition and market exposure. I prefer $30M settlement in one month and % royalties than $50M in June 2018 and implicit a CR. IMO
Ann: Phosphagenics Market Update - Potential Return of Capital, page-53
-
- There are more pages in this discussion • 119 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AVE (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.3¢ |
Change
0.000(0.00%) |
Mkt cap ! $9.507M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 48 | 86877619 | 0.2¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.3¢ | 60020911 | 20 |
View Market Depth
| Last trade - 16.12pm 21/08/2024 (20 minute delay) ? |
| AVE (ASX) Chart |
Day chart unavailable